NCT06502990 - Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Generalized Lipodystrophy

Interventions

DRUG

Metreleptin

Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency

Trial Locations (12)

3000

RECRUITING

UZ Leuven, Leuven

20251

NOT_YET_RECRUITING

Universitätsklinikum Hamburg-Eppendorf, Hamburg

21100

RECRUITING

Ospedale Filippo Del Ponte Varese - ASST Sette Laghi, Varese

28100

RECRUITING

Azienda Ospedaliero Universitaria Maggiore della Carità di Novara, Novara

43126

RECRUITING

Azienda Ospedaliero-Universitaria di Parma, Parma

56124

RECRUITING

Azienda Ospedaliero Universitaria Pisana, Pisa

66100

RECRUITING

IRCCS Ospedale Pediatrico Bambino Gesù, Chieti

75015

NOT_YET_RECRUITING

Hôpital Necker - Enfants Malades, Paris

80131

RECRUITING

"Azienda Ospedaliera Universitaria Federico II", Naples

89075

RECRUITING

Universitaetsklinikum Ulm - Klinik fuer Kinder- und Jugendmedizin, Ulm

Unknown

RECRUITING

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Universitaire Robert-Debre, Paris

00165

RECRUITING

IRCCS Ospedale Pediatrico Bambino Gesù, Rome